Business Wire

MARTINGALE-RISK

Share
Martingale Risk – Philips Shareholders Group Action to be Filed in the Netherlands

Martingale Risk, a specialist in global securities loss recovery, is originating a group action in the Netherlands against Philips on behalf of institutional investors, together with Grant & Eisenhofer as the Global Counsel and Old Haven Funding LLC as the Funder.

As reported by the U.S. regulator, the Food and Drug Administration (FDA), starting from at least October 2015, Philips was notified by customer complaints regarding its respiratory devices (sleep therapy devices used for the treatment of obstructive sleep apnea) causing potential health issues related to foam degradation. Upon receipt of this crucial information, Philips failed to proceed with any appropriate methods of risk analysis and to implement any corrective or preventive actions. Shareholders were not provided with any details regarding the severity of these matters nor the extent that Philips would be harmed financially, which in 2022 already resulted in €486 million in utilized provisions.

Following the June 14th, 2021 recall on millions of respiratory devices to address the health risks related to the foam, the FDA – that classified the recalls as Class I, the most serious type of recall – moved to swiftly investigate Philips, closing their investigation with several critical observations.

In response to an updated safety communication by the FDA, on Sept. 7th, 2023, Philips agreed to pay out at least $479 million to US consumers, as a means of managing and compensating for the health issues caused by its respiratory devices.

On April 4th, 2024, the FDA and the Department of Justice (DoJ) made a joint statement acknowledging Philips’ supposed failure to abide by the instructions and procedures of the remediation plan. This led to a recent Court-approved Consent Decree of Permanent Injunction (filed on April 9th, 2024), whereby Philips’ respiratory devices can no longer be manufactured or distributed from its US facilities, until they comply with various stringent reparative duties, as specified in the Recall Remediation Plan.

The finalization of the Consent Decree is undoubtedly a significant milestone for the protection of US-based consumers, yet action is still needed to further redress Philips’ misconduct, namely for institutional investors who purchased its equities, which were greatly impacted by Philips’ behavior. Martingale Risk, as the originator of the group action, will bring the proceedings in the Netherlands to recover its clients’ investment losses, which occurred throughout the period Nov. 2015-Nov. 2021.

Terms & Conditions:

Martingale Risk, together with Grant & Eisenhofer and Old Haven will be operating on a full contingent fee basis of the recovered amount as all legal, expert costs and expenses will be covered.

How to Proceed/Registration Deadline:

If your firm has invested or traded in Philips common stock and/or ADR from Oct. 30th, 2015-April 24th, 2023, please contact Mr. Marco Delzio (marco.delzio@martingalerisk.com) or Mr. Peter Ogden (peter.ogden@martingalerisk.com) for a free non-binding preliminary analysis.

The deadline to register for the proceedings is July 31st, 2024.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522190127/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Board Unveils New Foresight and Signals Products: Revolutionizing Business Planning with AI and Economic Intelligence19.2.2025 15:00:00 CET | Press release

Board, the leading Enterprise Planning Platform, is transforming the way businesses anticipate and adapt to economic shifts with today’s announcement of Board Foresight and Board Signals. These cutting-edge solutions, developed as a result of Board’s recent acquisition of Prevedere, empower enterprises with real-time economic indicators, predictive analytics, and the expertise of Board’s in-house economists—all backed by exclusive access to over 5 million global datasets. This release marks a huge step forward in completing Board’s product vision. By harnessing the power of macroeconomic intelligence, the Board Enterprise Planning Platform now enables more comprehensive, collaborative, and continuous planning capabilities than ever before. Board Foresight and Signals give business leaders the ability to look beyond internal historical data, forecast with greater accuracy, scenario plan with more agility, and make strategic decisions with confidence in an increasingly volatile world. Bo

PPG, PPG Foundation invested $18.4 million in communities worldwide in 202419.2.2025 15:00:00 CET | Press release

PPG (NYSE:PPG) and the PPG Foundation today announced that they invested $18.4 million worldwide in 2024, an increase of $900,000 over 2023. The 2024 funding supported more than 400 community partners and programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219834296/en/ PPG and the PPG Foundation invested $18.4 million worldwide in 2024 to programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. (Photo: Business Wire) “Around the world, PPG’s 2024 community engagement investments aimed to inspire students and aspiring STEM leaders, beautify neighborhoods and give our employees meaningful ways to give back,” said Malesia Dunn, executive director, PPG Foundation and corporate global social responsibility. “We’re focused on creating b

HSBC Continental Europe: 2024 Annual and Second Half Results19.2.2025 14:40:00 CET | Press release

Regulatory News: On 18 February 2025, HSBC Continental Europe’s Board of Directors reviewed the second half year results and approved the consolidated financial statements for 2024. At HSBC, our ambition is to be the preferred and most trusted international financial partner for our clients. In Continental Europe, we are focused on serving corporate and institutional clients, with a particular focus on connecting them to international markets, financing and facilitating trade within Europe and between Europe and the rest of the world. We also serve international high and ultra-high net worth clients of the HSBC Group through our private banking business in Luxembourg. In the second half of 2024, we accelerated our strategy by signing an agreement to sell our private banking business in Germany and a Memorandum of Understanding for the potential sale of our life insurance business in France1. Our results in 2024 reflected growth in wholesale transaction banking and financing, offset by

Parse Biosciences Launches 5 Million Cell Evercode WT Penta Kit for Single Cell Sequencing19.2.2025 14:15:00 CET | Press release

The most scalable and high-resolution single cell solution available Parse Biosciences, the leader in high-throughput single cell sequencing, today announced the launch of Evercode™ WT Penta and Penta 384, the first single cell RNA sequencing kits to profile 5 million cells and 384 samples in a single run. Evercode Penta and Penta 384 will begin shipping to customers the week of March 17. Scaling up single cell experiments—processing millions of cells instead of thousands—has revolutionized the way researchers study development, disease, and cellular heterogeneity. In 2021, Parse set a new benchmark for scalability of single cell experiments with the release of Evercode™ WT Mega, the industry’s highest throughput kit, enabling researchers to push the boundaries of their experimental designs. With the release of Evercode WT Penta, Parse continues to redefine the limits of single cell research. Penta is the only technology offering fixation and truly unbiased discovery of novel gene expr

Celerion Expands UK Phase 1 Clinical Research Operations With New Agreement to Relocate to Queen’s University Belfast’s iREACH Health – Clinical Research Innovation Center19.2.2025 14:00:00 CET | Press release

Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health. This state-of-the-art clinical research center, led by Queen’s University Belfast, in partnership with the Belfast Health and Social Care Trust, is set to become a cornerstone of Northern Ireland’s life sciences innovation ecosystem upon its early 2027 completion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219467591/en/ Set to complete in 2027, the state-of-the-art iREACH Health clinical research center is set to become a cornerstone of Northern Ireland's life sciences landscape. As part of this development, Celerion will relocate its U.K. Phase 1 clinical research operations to the facility, positioning it at the forefront of clinical research innovation. (Photo: Business Wire) Celerion’s Belfast clinic has a history of clinical research excellence spannin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye